Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcerative Clear all
Not yet recruiting Phase 2 Interventional

Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

NCT07767864
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Bimekizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 1, 2026, 5:03 PM EST
Completed No phase listed Observational Accepts healthy volunteers

OTIS Vedolizumab Pregnancy Exposure Registry

NCT02678052
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab, Other Biological Agent
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Nov 1, 2026, 5:03 PM EST
Completed Phase 4 Interventional Results available

Ulcer Prevention Study in Post Gastric Bypass Patients

NCT00557349
View directory record Official record
Conditions
Marginal Ulcers
Interventions
Omeprazole, Famotidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Nov 1, 2026, 5:03 PM EST
Completed Phase 2 Interventional

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

NCT04857112
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 1, 2026, 5:03 PM EST
Not listed Phase 2 Interventional

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893
View directory record Official record
Conditions
Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Placebo, VF001-DP LD, VF001-DP HD
Biological
Lead sponsor
Factor Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Not applicable Interventional

Pilot Study Comparing Negative Pressure Dressings to Conventional Dressings

NCT03450616
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
PICO Negative Pressure Wound Therapy, Compression Dressing
Device · Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Not applicable Interventional

Pressure Ulcer Prevention for SCI Using a Tele Home Program

NCT01166828
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
TELLEPUPPS
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Nov 1, 2026, 5:03 PM EST
Completed Phase 1Phase 2 Interventional Results available

Anakinra for Behcet s Disease

NCT01441076
View directory record Official record
Conditions
Autoimmune Connective Tissue Disorder, Immune System Diseases
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Nov 1, 2026, 5:03 PM EST
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02315417
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
gevokizumab, Placebo, gevokizumab open-label
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Coral Gables, Florida • North Miami Beach, Florida • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Nov 1, 2026, 5:03 PM EST
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT03650413
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Nov 1, 2026, 5:03 PM EST
Recruiting No phase listed Observational

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

NCT04372108
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Ustekinumab, Other Biologic Therapies
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 1, 2026, 5:03 PM EST
Completed Phase 2 Interventional

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191
View directory record Official record
Conditions
Gastrinoma, Zollinger Ellison Syndrome
Interventions
Pantoprazole, Omeprazole
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 5:03 PM EST
Recruiting Not applicable Interventional

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

NCT06606210
View directory record Official record
Conditions
Wound Heal, Venous Leg Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
North Port, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 1, 2026, 5:03 PM EST
Terminated Not applicable Interventional

An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds

NCT05494450
View directory record Official record
Conditions
Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions
ExufiberAG+
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
San Francisco, California • Miamisburg, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 1, 2026, 5:03 PM EST
Recruiting Not applicable Interventional

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, PuraPly AM, PuraPly XT
Other · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Clevland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Not applicable Interventional

Vitamin D Treatment in Ulcerative Colitis

NCT01640496
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vitamin D3, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Nov 1, 2026, 5:03 PM EST
Terminated Not applicable Interventional Results available

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

NCT03626623
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 1, 2026, 5:03 PM EST
Completed No phase listed Observational Results available

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

NCT02438410
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Not applicable Interventional

The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers

NCT00815217
View directory record Official record
Conditions
Diabetic Wounds, Venous Stasis Wounds
Interventions
injection of lipoaspirate, control
Procedure · Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 1, 2026, 5:03 PM EST
Recruiting Phase 4 Interventional

Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers

NCT05217160
View directory record Official record
Conditions
Wound of Skin, Burns
Interventions
KeraStat® Gel with Morphine application, KeraStat® Gel application
Drug
Lead sponsor
The Metis Foundation
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Nov 1, 2026, 5:03 PM EST
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Phase 1Phase 2 Interventional

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

NCT04058197
View directory record Official record
Conditions
Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions
Deferoxamine Product, Placebo
Drug · Other
Lead sponsor
TauTona Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Nov 1, 2026, 5:03 PM EST
Completed Phase 2 Interventional

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

NCT04817228
View directory record Official record
Conditions
Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions
EscharEx (EX-02 formulation)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 1, 2026, 5:03 PM EST
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Nov 1, 2026, 5:03 PM EST